TABLE 1.
Characteristics of OXA-58-producing A. pittii isolates from companion animals in Germany
| Strain | Date of isolation | Host | Sample (disease) | Other bacteria isolated | Veterinary clinic | Pulsotype | ST | Antimicrobial resistancea | Resistance genes |
|---|---|---|---|---|---|---|---|---|---|
| IHIT24944 | 2/2014 | Dog 1 | Nose swab (rhinitis, sinusitis) | Acinetobacter baumannii, Bacillus sp. Micrococcus sp. | A | A | 93 | FEP, CTZ, FEP, CFP, CTU, GEN, CIP, MOX, ENR, MAR, TET, TOB, NIT, SXT | aacC2, aph(3′)-Ic, strA, strB, sul2, blaOXA-500, blaADC-18-like, blaOXA-58, tet(39) |
| IHIT32473 | 7/2016 | Dog 2 | Bronchial fluid (respiratory tract infection) | Acinetobacter johnsonii, Pseudomonas sp., Candida sp. | A | A | 93 | FEP, CTZ, FEP, CFP, CTU, CPD, GEN, CIP, MOX, ENR, MAR, TET, TOB, NIT, SXT | aacC2, aph(3′)-Ic, strA, strB, sul2, blaOXA-500, blaADC-18-like, blaOXA-58, tet(39) |
| IHIT32685 | 9/2016 | Rabbit | Nose (none, screening) | Bacillus sp., Candida sp., Streptococcus sp. | A | A | 93 | FEP, CTZ, FEP, CFP, CTU, CPD, GEN, CIP, MOX, ENR, MAR, TET, TOB, NIT, SXT | aacC2, aph(3′)-Ic, strA, strB, sul2, blaOXA-500, blaADC-18-like, blaOXA-58, tet(39) |
| IHIT29469 | 5/2015 | Cat 1 | Nose swab (suppurating rhinitis) | Bordetella bronchiseptica, Staphylococcus simulans, Micrococcus sp. | B | B | 93 | CPD, CTU, GEN, CIP, MOX, ENR, TET, NIT, SXT | aacC2, aph(3′)-Ic, strA, strB, sul2, blaOXA-500, blaADC-18-like, blaOXA-58, tet(39) |
| IHIT29592 | 6/2015 | Cat 2 | Skin swab (purulent dermatitis) | Acinetobacter sp., Bacillus sp., Pasteurella multocida | B | B | 93 | CPD, CTU, CFP, GEN, CIP, MOX, ENR, TET, NIT, SXT | aacC2, aph(3′)-Ic, strA, strB, sul2, blaOXA-500, blaADC-18-like, blaOXA-58, tet(39) |
All isolates were resistant to ampicillin (AMP), amoxicillin-clavulanate (AMC), chloramphenicol (CHL), fosfomycin (FOS), cephalexin (LEX), and piperacillin (PIP) in accordance with the definitions of intrinsic resistance for members of the Acinetobacter baumannii complex set by EUCAST and CLSI. All isolates were susceptible to amikacin (AMK), imipenem (IPM), meropenem (MER), polymyxin B (PMB), tigecycline (TGC), tobramycin (TOB), and piperacillin/tazobactam (TZP). CPD, cefpodoxime; CTZ, ceftazidime; FEP, cefepime; CFP, cefpirome; CTU, ceftiofur; ENR, enrofloxacin; GEN, gentamicin; MAR, marbofloxacin; TET, tetracycline; SXT, sulfamethoxazole-trimethoprim; CIP, ciprofloxacin; MOX, moxifloxacin; FOS, fosfomycin; NIT, nitrofurantoin; CHL, chloramphenicol; TZP, piperacillin-tazobactam.